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Abstract: MicroRNAs (miRNAs) have a critical role in regulating stem cells (SCs) during development,
and because aberrant expression of miRNAs occurs in various cancers, our goal was to determine
if dysregulation of miRNAs is involved in the SC origin of colorectal cancer (CRC). We previously
reported that aldehyde dehydrogenase (ALDH) is a marker for normal and malignant human colonic
SCs and tracks SC overpopulation during colon tumorigenesis. MicroRNA expression was studied in
ALDH-positive SCs from normal and malignant human colon tissues by Nanostring miRNA profiling.
Our findings show that: (1) A unique miRNA signature distinguishes ALDH-positive CRC cells
from ALDH-positive normal colonic epithelial cells, (2) Expression of four miRNAs (miRNA200c,
miRNA92a, miRNA20a, miRNA93) are significantly altered in CRC SCs compared to normal colonic
SCs, (3) miRNA92a expression is also upregulated in ALDH-positive HT29 CRC SCs as compared to
ALDH-negative SCs, (4) miRNA92a targets the 30 UTR of LRIG1 SC gene, and (5) miRNA92a modulates
proliferation of HT29 CRC cells. Thus, our findings indicate that overexpression of miRNA92a
contributes to the SC origin of CRC. Strategies designed to modulate miRNA expression, such as
miRNA92a, may provide ways to target malignant SCs and to develop more effective therapies
against CRC.
Keywords: microRNA; miRNA92a; stem cells; LRIG1, colon; human; crypts

1. Introduction
A significant body of scientific evidence indicates that: (i) stem cells (SCs) are the cells of origin of
cancer [1,2], (ii) SC overpopulation drives tumor initiation and progression [3–5], (iii) SCs are resistant
to conventional anti-cancer therapies. We discovered that aldehyde dehydrogenase (ALDH) is a
marker for normal and malignant human colonic SCs and tracks SC overpopulation during colon
tumorigenesis [5]. While our findings on ALDH and many results on various SC markers by others
indicates that cancer SC (CSC) overpopulation drives tumor growth, it is not fully understood which
dysregulated mechanisms cause the SC overpopulation. Because evidence indicates miRNAs have an
important role in the pathogenesis of various cancers, we have been studying changes in miRNAs
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as a possible mechanism in colorectal cancer (CRC). Indeed, aberrant expression of miRNAs leads to
wide-spread transcriptional dysregulation and cancer [6–10]. In CRC, differential miRNA expression
has been related to stage and site of the tumor [11]. Mounting evidence also indicates a role for miRNAs
in the maintenance of the CSC phenotype [12–16]. We have been focusing on miRNAs that contribute
to maintenance of the phenotype of colonic CSCs.
Indeed, a previous study of ours was designed to analyze miRNA expression in the colonic SC niche
using micro-dissected human colonic crypts. In that study we identified a set of miRNAs that is specific
to the normal colonic SC niche and distinguishes malignant from normal epithelia [17,18]. Notably,
miRNA23b, which was increased in CRC, was predicted to target the SC-expressed G protein-coupled
receptor LGR5. Further investigations showed that miRNA23b regulates CSC phenotypes globally
at the level of proliferation, cell-cycle, self-renewal, EMT, invasion, and resistance to the CRC
chemotherapeutic agent 5-FU. We also found that miRNA23b decreased LGR5 expression and increased
the number of ALDH-positive CSCs. CSC analyses confirmed that levels of LGR5 and miRNA23b are
inversely correlated in ALDH-positive CSCs and that CRC tissues contain distinct sub-populations of
LGR5-positive and ALDH-positive CSCs. Overall, our previous study defined a critical function for
miRNA23b, which, by targeting LGR5, contributes to overpopulation of ALDH-positive CSCs and CRC.
In the current study, we took a different approach to identify miRNAs in colonic SCs based on a
more extensive screen that involved miRNA expression profiling of ALDH-positive SCs isolated from
normal colonic epithelium and CRC tissue. This broader approach was done to identify additional
miRNAs that might be involved in the SC origin of CRC development. Accordingly, we used nCounter
miRNA profiling (Nanostring Technologies) to analyze miRNA expression in purified ALDH-positive
cells from human CRCs and normal colonic epithelium (NCE). We hypothesized that specific miRNAs
are selectively expressed in the normal ALDH-positive SCs, and that some or all of these miRNAs
contribute to SC mechanisms involved in CRC growth during tumor development. Our initial goal
was to identify the set of miRNAs and their target genes that are specific to the normal colonic
ALDH-positive SCs. Our second goal was to identify specific miRNAs in that set that are aberrantly
expressed in CRC ALDH-positive CSCs. Our third goal was to see if some of these miRNAs are
predicted to target known SC marker genes, and whether they contribute to the SC origin of CRC.
2. Results
2.1. Identification and Isolation of ALDH-Positive Normal and Malignant Human Colonic Stem Cells
To identify ALDH-positive SCs in viable human tissues, isolated human colonic crypts as well as
freshly dissociated normal and malignant colonic cells, were subjected to the ALDEFLUOR assay in the
presence or absence of the DEAB inhibitor of ALDH activity. Fluorescence microscopy analysis showed
that cells at the bottom of normal colonic crypts display intense green fluorescence signal indicating
that cells in the crypt SC niche have high ALDH activity (Figure 1A,B). Fluorescence microscopic
analysis of dissociated cells derived from both fresh normal crypts and CRC tissues also showed
that these colonic tissues contain specific subpopulations of ALDEFLUOR-positive (green stained)
cells (Figure 1C). These results indicate that high ALDH activity specifically marks colonic SCs in
fresh viable normal and malignant colonic tissues. Flow cytometric cell sorting was then used to
isolate SCs from fresh normal and tumor patient samples. Cells that co-stained for both ALDEFLUOR
and EpCAM (for marking carcinoma cells) were sorted along with those that were EpCAM-positive
and ALDEFLUOR-negative. ALDEFLUOR-positive and negative cells from five pairs of matched
normal and tumor tissues were sorted (Figure 1D). The proportion of ALDEFLUOR-positive cells
in the different cell populations isolated from patient samples are given in Supplementary Table S1,
which represents cells that were purified for miRNA expression analysis. For normal colon, the
percent ALDEFLUOR-positive cells (3.8 ± 2.2%) from flow cytometry concurs with the percent (5.6%)
reported by quantitative immunohistochemical mapping [5]. For colon carcinomas, the number of
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ALDEFLUOR-positive cells (~2%) in any given malignancy (109 –1013 cells) indicates that a large
3 of 15
increase in absolute number of CSCs occurs during tumor development.
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We then selected those miRNAs from this set that showed a statistically significant difference
(p < 0.05) in expression in tumor CSCs compared to normal SCs. Specifically, our miRNA profiling
identified significantly altered expression (p < 0.05) of miRNA200c, miRNA92a, miRNA20a and
miRNA93 in ALDEFLUOR-positive tumor CSCs as compared to ALDEFLUOR-positive normal SCs
(Supplementary Figure S2). This sub-set of miRNAs was analyzed further to identify SC marker genes
that are targeted by those miRNAs that are differentially expressed in tumor ALDEFLUOR-positive
stem cells. Accordingly, miRNA target prediction tools (rna22 and TARGETSCAN) were used to see
if any of the miRNAs are predicted to target known colonic SC markers. This analysis revealed that
miRNA92a is predicted to target the 30 UTR of the LRIG1 SC gene. Thus, we selected miRNA92a for
Int.
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Sci. 2020, 21,
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2.3. miRNA92a Shows Differential Expression in ALDEFLUOR-Positive Cancer Stem Cells and Targets the
2.3. miRNA92a Shows Differential Expression in ALDEFLUOR‐Positive Cancer Stem Cells and Targets the
LRIG1 Stem Cell Marker Gene
LRIG1 Stem Cell Marker Gene
We identified multiple differentially expressed miRNAs in colon cancers that have also been
We identified multiple differentially expressed miRNAs in colon cancers that have also been
investigated and reported for having a role in cancer stem cells [19–21]. We decided to focus our
investigated and reported for having a role in cancer stem cells [19–21]. We decided to focus our
attention on the miRNAs of 17–92 cluster [22], particularly miRNA92a, which has not been extensively
attention on the miRNAs of 17–92 cluster [22], particularly miRNA92a, which has not been extensively
investigated in the context of regulation of cancer stem cells. To evaluate a role of miRNA92a in
investigated in the context of regulation of cancer stem cells. To evaluate a role of miRNA92a in
colonic SCs, expression of miRNA92a was further analyzed in ALDEFLUOR-positive and negative
colonic SCs, expression of miRNA92a was further analyzed in ALDEFLUOR‐positive and negative
SCs from fresh human colonic tissues and from the HT29 CRC cell line. Results show that miRNA92a
SCs from fresh human colonic tissues and from the HT29 CRC cell line. Results show that miRNA92a
expression is up‐regulated in ALDEFLUOR‐positive tumor cells compared to ALDEFLUOR‐positive
normal colonic cells from patient samples (Figure 3A). Further analysis of the HT29 cell line showed
that miRNA92a expression is significantly upregulated in ALDEFLUOR‐positive cells as compared to
ALDEFLUOR‐negative HT29 cells (Figure 3B). A proliferation assay was then done to assess the effect
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expression is up-regulated in ALDEFLUOR-positive tumor cells compared to ALDEFLUOR-positive
normal colonic cells from patient samples (Figure 3A). Further analysis of the HT29 cell line showed
that miRNA92a expression is significantly upregulated in ALDEFLUOR-positive cells as compared
to ALDEFLUOR-negative HT29 cells (Figure 3B). A proliferation assay was then done to assess the
effect of this miRNA on the growth of colon cancer cells. Cell growth analysis showed that transfection
with miRNA92a antimir significantly reduces proliferation of HT29 CRC cells and transfection with
miRNA92a precursor siRNA has the opposite effect on proliferation (Figure 3C).
Because miRNA target prediction tools revealed that miRNA92a targets the LRIG1 SC gene,
we used luciferase assay to validate this target prediction. This luciferase assay employed a plasmid
reporter that expresses luciferase and a 30 UTR of the predicted target LRIG1 gene. This assay revealed
a significant
decrease
in PEER
the relative
Int.
J. Mol. Sci. 2020,
21, x FOR
REVIEWluminescence intensity in transfected HT29 cells as compared
6 of to
15
the control providing evidence that miRNA92a targets the LRIG1 30 UTR (Figure 3D).

Figure 3. MicroRNA92a is overexpressed in ALDEFLUOR positive cells and regulates the LRIG1 gene
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3. Discussion

3. Discussion
The main findings of our study are: (1) a set of miRNAs are selectively expressed in normal
colonic
(2)study
specific
set are are
aberrantly
expressed
in CRC
CSCs,
TheALDH-positive
main findings SCs,
of our
are:miRNAs
(1) a setinofthis
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expressed
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colonic
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SCs,
(2) specific
miRNAs
in this settargets
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(3) one of these aberrantly expressed miRNAs, miRNA92a, targets the 3′UTR of the LRIG1 SC gene,
and (4) miRNA92a regulates proliferation of human CRC cells. Our results support our hypothesis
that specific miRNAs are selectively expressed in normal ALDH‐positive SCs, and that some or all of
these miRNAs contribute to SC mechanisms involved in CRC growth and development. Several
points related to these findings bear further discussion.
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and (4) miRNA92a regulates proliferation of human CRC cells. Our results support our hypothesis
that specific miRNAs are selectively expressed in normal ALDH-positive SCs, and that some or all
of these miRNAs contribute to SC mechanisms involved in CRC growth and development. Several
points related to these findings bear further discussion.
3.1. What Is the Biological Significance of Differentially Expressed miRNAs in ALDH-Positive Colonic SCs?
There were several miRNAs that showed a differential expression in ALDH positive cells of the
tumor compared to the ALDH positive cells of matched normal tissue. These findings suggest that
dysregulation of these miRNAs results in transformation of normal SCs into tumor SCs. Our profiling
results identified some members, particularly miRNA200c, of the miRNA200 family of miRNAs that
are aberrantly expressed in CRC CSCs. The miRNA200 family consists of 5 members which have been
shown to play key roles in cancer initiation and metastasis. For example, Shimono et al., reported
that downregulation of miRNA-200c links breast cancer SCs with normal stem cells [19]. Moreover,
we found some Let-7 family members were differentially expressed in tumor ALDH-positive cells.
Let-7 was one of the first miRNAs shown to have a role in breast cancer initiating cells. It was
downregulated in breast CSCs and induction of Let-7 expression inhibited their self-renewal [23].
MicroRNA93 is an interesting candidate miRNA because it is downregulated in tumor SCs compared
to normal SCs. MicroRNA93 expression has also been reported to be significantly decreased in colon
tumors compared to the normal counterpart and has been associated with stage and outcome of the
tumor [20]. In breast cancer cells, increased expression of miRNA93 induced MET (reverse of EMT),
downregulated multiple SC-associated genes, and depleted CSC populations [21]. Moreover, in the
colon cancer cell line SW116, miRNA93 was found to be downregulated and then when upregulated,
it was shown to suppress proliferation and colony formation [24].
We also showed that miRNA92a and miRNA20a are differentially expressed in patient-derived
CSCs. Both these miRNAs are a part of the oncogenic miRNA17–92 cluster [24–27], which was predicted
to target LRIG1 [28,29]. The miRNA 17–92 cluster is upregulated in various forms of cancers such as
hepatocellular and gastric carcinomas [30,31]. Moreover, members of this cluster have been reported
to have a role in maintaining self-renewal of gastric CSCs by modulating levels of inhibitors of the
WNT signaling pathway [31]. Moreover, miRNA20a was found to be overexpressed in prostate cancer
and to be involved in metastasis and invasion [32]. High expression levels of the miRNA17-92 cluster
have also been reported to have prognostic value in CRC [33]. Indeed, our miRNA profiling revealed
that both miRNA20a and miRNA92a have significantly altered expression in ALDEFLUOR-positive
tumor cells as compared to ALDEFLUOR-positive normal cells. However, our data showed that only
miRNA92a was differentially expressed in the ALDELFUOR-positive HT29 CRC cells. Thus, among the
differentially expressed miRNAs that we found in ALDH-positive colonic CSCs, miRNA92a appeared
to have the most biological relevance in CRC.
3.2. What Is the Biological Significance of miRNA92a in Carcinogenesis?
Our further analysis of miRNA92a showed that it regulates proliferation of human CRC cells.
Similarly, miRNA92a has been reported to have a role in regulating proliferation of a number of cancer
types [34]. For example, miRNA92a has been reported to be a critical regulator of the apoptosis pathway
in glioblastoma and lymphoma. Specifically, miRNA92a has anti-apoptotic activity via inhibition of the
pro-apoptotic protein BIM and inhibition of miRNA92a leads to induction of cell death [35,36]. In fact,
down-regulation of miRNA92 in human plasma is a novel marker for acute leukemia patients [37].
Moreover, miRNA92a was observed to promote tumor growth of osteosarcoma by targeting the
PTEN/AKT signaling pathway [38]. Additionally, deregulation of miRNA92a expression has been
implicated in hepatocellular carcinoma [39], and, in breast cancer, estrogen receptor expression was
reported to be regulated by miRNA92a [40]. Other studies have also reported on the function of
miRNA92a in CRC development. In one study, overexpression of miRNA92a correlated with tumor
metastasis and poor prognosis in patients with CRC [41]. In a recent report, Alcantara and Garcia [42]
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found that miRNA92a promotes cell proliferation, migration and survival by directly targeting the
tumor suppressor gene NF2 in colorectal and lung cancer cells. Tsuchida et al. [26] found that increased
expression of miRNA92a occurs in colonic adenomas and in CRCs, miRNA92a directly targets BMI
and inhibits CRC cell apoptosis. In addition, miRNA92a inhibitor induces CRC cell apoptosis. In two
other studies [43,44], miRNA92a in feces and plasma was found to serve as a biomarker for patients
with colon tumors. Taken together, these reports indicate that miRNA92a has an important role in the
pathological development of many cancer types, including CRC.
3.3. What Is the Role of miRNA92a in the Stem Cell Origin of Cancer?
MicroRNAs contribute to the progressive changes in gene expression that occur during
development [45]. Indeed, expression patterns of many miRNAs are timing- and organ-specific,
particularly miRNAs involved in the regulation of development. Notably, the miRNA92a family has
an important role in regulating the development of mammalian organs including heart, lungs and
immune system as well as the formation of blood vessels [35]. That miRNA92a has a critical role in
development suggests that it regulates SCs during development [46]. For example, analyses of miRNA
libraries have shown miRNA92 to be expressed in mouse embryonic stem cells [47]. Such totipotent SCs
represent the earliest stages of mammalian development because they are derived from the inner cells
of the blastocyst. While miRNAs have a role in embryonic SCs and aberrant expression of miRNAs
occurs in various cancers, their role in the SC origin of cancer is not very well understood.
Our findings herein show that miRNA92a downregulates LRIG1 expression by targeting LRIG10 s
0
3 UTR region. We also observed that increasing miRNA92a levels increases CRC cell numbers and
vice versa. Moreover, miRNA92a expression is upregulated in ALDEFLUOR-positive colonic CSCs.
And, we found that ALDH-positive cells in CRCs do not express LRIG1 [48]. To understand the
implications of our results indicating that expression of miRNA92a and LRIG1 are inversely correlated
in ALDH-positive CSCs, we need to understand how our findings relate to LRIG10 s known functional
roles. Notably, LRIG1 is known as a pan-ERBB negative regulator and it is well established that LRIG1
promotes SC quiescence especially in epidermis and the GI tract system [33,49].
This raises the question: How does upregulated miRNA92a and reduced LRIG1 affect the
proliferative state of ALDH-positive colonic CSCs? We have recently studied the quiescence properties
of human colonic crypt cells [50]. We found that several kinetic mechanisms regulate quiescence of
normal crypt cells. And during CRC development, dysregulation of these kinetic mechanisms induces
changes in crypt cell quiescence associated with the increased number of proliferative cells that occurs
in colonic tumors. We also know that ALDH is a key component of the retinoid signaling pathway and
ALDH-positive SCs directly differentiate into neuroendocrine cells [51]. Thus, we hypothesize that
upregulated miRNA92a, by down-regulating LRIG1, decreases differentiation and increases proliferative
potential of ALDH-positive CSCs. In this way, dysregulated expression of miRNA92a may contribute
to CSC overpopulation that drives an increase in proliferative cells during CRC development and
growth [3–5,52].
4. Materials and Methods
Isolation of colonic epithelium. The use of human clinical samples in this study was approved by the
Thomas Jefferson University and Christiana Care Health System IRBs. Informed written consent was
obtained from the subjects (wherever necessary). The patient studies were conducted in accordance
with the following ethical guidelines: Declaration of Helsinki, International Ethical Guidelines for
Biomedical Research Involving Human Subjects (CIOMS), Belmont Report, and U.S. Common Rule.
Colon tissues removed from patients during surgery were collected during or immediately after
surgery and crypts were isolated as we previously described [53–55]. All tissue samples (n = 5) were
patient-matched (i.e., tumor and normal tissues were derived from the same patient).
Isolation of Crypts. Normal and tumor tissue were washed three times in sterile PBS. The normal
tissue was carefully cleaned of the muscle layer using clean forceps and surgical scissors. It was then
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placed in 3.0 mM solution of EDTA containing DTT and incubated on ice for 60–90 min. The crypts
were separated from the submucosa by rigorous shaking of the tissue in solution for five minutes.
The isolated crypts were washed with sterile PBS thrice.
Dissociation of Normal and Tumor Tissue to Single Cells. Single cell dissociation of normal epithelium
was achieved by treating the crypts with collagenase IV (Worthington Inc., Lakewood, NJ) solution
in HBSS (10 mg/mL) and DNase I (Worthington Inc., Lakewood, NJ) for 60–90 min at 37 ◦ C. Tumor
tissue was cut into small pieces using a sterile scalpel and incubated in collagenase/hyaluronidase and
DNase I solution in HBSS to achieve enzymatic digestion of the tissue to single cells. Cells from both
normal and tumor tissue were washed thrice with HBSS.
Identification of ALDH-positive Colonic Stem Cells in Fresh Viable Tissue Samples. To detect ALDH
activity in the bottom of fresh normal isolated crypts, single dissociated crypts were obtained after
60 min of dissociation from normal epithelium. These isolated colonic crypts, as well as fresh
dissociated normal and tumor cells, were then subjected to ALDEFLUOR assay in the presence
or absence of the DEAB inhibitor of ALDH activity. The detection of green fluorescence staining,
which indicates high ALDH activity, was analyzed using a Zeiss Epi-fluorescence microscope using the
10X objective. The cells identified with high ALDH activity were then isolated using flow cytometry as
described below.
Overall Strategy. Our study analyzed all the patient samples that were processed and produced
RNA that passed quality control for profiling. Briefly, fresh tissue tumor/normal tissue pairs were
obtained from five patients for processing and analysis. Specifically, we sorted using FACS, four different
sorted cell populations from each of the patients for profiling: (1) PI-negative/ALDH-positive from
normal tissue, (2) PI-negative/ALDH-negative from normal tissue, (3) EPCAM-positive/ALDH-positive
from tumor tissue, and (4) EPCAM-positive/ALDH-negative from tumor tissue. We then isolated RNA
from each of these 20 purified cell populations and only those RNA isolates that passed rigorous quality
control standards were then analyzed by miRNA profiling. The RNA samples from four patients
passed quality control and were analyzed for expression of 800 miRNAs using Nanostring profiling.
This analysis of these multiple samples gave 12,800 data points for statistical analysis.
Analysis of this data from multiple patients gives the combined pattern of miRNA expression
across the profiling of RNA from all four different isolated cell populations from all four of the patients.
Statistical analysis provided two data sets: (i) the top set of miRNAs that showed a substantial difference
in expression (<0.1) between tumor ALDEFLUOR-positive stem cells and ALDEFLUOR-positive
normal stem cells, and (ii) a sub-set that showed a statistically significant difference (p < 0.05) in
expression. This sub-set of miRNAs was analyzed further to identify SC marker genes that are targeted
by the miRNAs that are differentially expressed in tumor ALDEFLUOR-positive stem cells compared
to ALDEFLUOR-positive normal stem cells. Specific details on methods are given below.
ALDEFLUOR Assay, Propidium Iodide Staining and EpCAM Staining of Normal and Tumor cells.
ALDEFLUOR-positive cells were isolated as described previously [5,17,51,56]. The dissociated cells
from both normal and tumor were washed thrice in sterile HBSS and then subjected to the ALDELFUOR
Assay following the manufacturer’s protocol (STEMCELL Technologies Inc., BC, Canada). The cells
were spun down at room temperature and resuspended in ALDEFLUOR buffer. The cell suspension
was divided into three tubes: ALDEFLUOR only, ALDEFLUOR + DEAB (inhibitor) and Blank.
The tubes were incubated in the dark at 37 ◦ C for 25 min. After incubation, the cells were spun down
once and resuspended in ALDEFLUOR buffer. The cells suspension was transferred to a FACS sample
tube through a 50-micron filter. The samples were run on the BD FACSAria II using the FACSDiva
Software. The gates were drawn to eliminate doublets and to include 0.1% in the positive gate of cells
in the respective DEAB control and appropriate ALDEFLUOR positive samples. Normal dissociated
tissue was stained for propidium iodide to identify live cells following the ALDEFLUOR staining.
Cells were incubated in ALDEFLUOR buffer containing PI stain at a concentration of 1 µg/mL for
20 min at RT in the dark. Cells were washed once with ALDEFLUOR buffer and were stored on ice
under further analysis. Tumor cells, after the ALDEFLUOR assay, were incubated with an APC-labeled
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EpCAM antibody (1:100, BioLegend Inc., San Diego, CA) for 1 h on ice in the dark. EpCAM staining
was used to select colon carcinoma cells and exclude contaminating stromal cells from tumor tissues.
The sorted cells were washed twice with ALDEFLUOR buffer and were stored on ice until they were
subjected to FACS analysis.
Cell Sorting by Flow Cytometry. The 85-micron or the 100-micron nozzle was used for the sorting
experiment. The stream was turned ON and was Cytometer setup and Tracking was done to calibrate
the machine. Accudrop experiment was carried out to determine the delay between the drops prior to
any sorting. A test sort was done to ensure proper collection of sample in the collection tubes. The dot
plots were created and the cell populations were appropriately chosen to eliminate doublets out of the
analysis. The blank sample was run through FACS initially. Voltage of FSC and SSC were adjusted if
needed to set the cell population in the center of the first dot plot. Appropriate regions within the plots
were selected so that only single cells could be sorted. The sample with the DEAB control was run
through FACS and data was recorded. The ALDH alone (green only) and the PI alone (red only for
normal) or EpCAM only (red only for tumor) samples were run to calculate compensation between the
two fluorophores to eliminate cross talk in the analysis. Using the DEAB alone sample, the gates for
the ALDEFLUOR negative and ALDEFLUOR positive were created in the dot plot for SSC vs FITC.
Similarly, gates for additional controls (PI and EpCAM) were also created using the blank sample.
For normal tissue, PI negative samples were regarded as alive and were gated for ALDEFLUOR
positive or negative cells. For the tumor samples, EpCAM positive cells were selected and gated
for ALDEFLUOR-positive and ALDEFLUOR-negative cells. After quality control, we obtained four
different sorted samples from each pair: PI-negative/ALDH-positive and PI-negative/ALDH-negative
from normal tissue and EPCAM-positive/ALDH-positive and EPCAM-positive/ALDH-negative from
tumor tissue. These four pairs of sorted samples were used for isolation of RNA and analysis by
miRNA profiling.
Cell Lines. The HT29 cell line was purchased from ATCC Inc., (Manassas, VA; year 2013;
authenticated by the provider by cytogenetic analysis). Cells were grown in McCoys media (GIBCO)
containing 10% FBS and 1% Penicillin/Streptomycin. The cells were grown in 5% CO2 and 95% air at
37 ◦ C. All the experiments were carried out in triplicate and within 10 passages after being thawed.
The cells were routinely tested for mycoplasma by Universal mycoplasma detection kit by ATCC.
RNA Isolation. RNA isolations were performed according to the manufacturer’s protocol using the
Trizol Reagent (Life Technologies Inc., Carlsbad, CA). One mL of Trizol was added per million cells and
incubated at 4 ◦ C for ten minutes. Chloroform (0.2mL per ml of Trizol used) was added to the cells and
the solution was mixed vigorously for 15 s. The tubes were placed on ice for two min and then spun at
12,000 rpm at 4 ◦ C for 15 min. Following centrifugation, the upper clear layer was carefully removed
from each sample and transferred to a new tube. RNA was precipitated by adding isopropanol (0.5 mL
per 1 mL of Trizol added) to the tube, followed by incubation for 10 min on ice. Spinning down the
solution at 12,000 rpm for ten minutes at 4 ◦ C pelleted the precipitated RNA. The supernatant was
discarded and the RNA was washed twice by spinning down the pellet in 1 mL of ice cold 70% ethanol
per ml of Trizol used. The pellet was allowed to air dry and was dissolved in nuclease free water.
RNA Quantification. RNA quantification was done by determining the absorbance of samples
at two wavelengths (260 and 280 nm) using the plate reader (TECAN) and the Nanoquant plate.
Two µl of sterile water was used for blanking the instrument, followed by 2 µL of the RNA sample.
The concentration values provided by the instrument were taken in triplicates and averages were
calculated for each RNA sample.
MicroRNA Analysis. The RNA samples were concentrated to get a minimum concentration of
33 ng/µL by using 3.0 M Sodium acetate and glycogen as a carrier molecule. The samples were sent
to Nanostring Technologies Inc. (Seattle, WA) for profiling. Nanostring Technologies made use of a
unique set of color-coded fluorescent probes, which is hybridized to mature miRNA with the help of a
linker molecule. This approach has the advantage of quantitation of miRNA levels in a cell population
and requires as little as 150 ng of total RNA per sample.
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The results were presented as raw counts for each of the miRNAs as well as several negative
and positive controls. This data was then imported to NSolver 4.0 software. The software takes
the average of the whole data set and ranks the miRNAs with the highest positive and negative
values from the average. Each measured miRNA species in each sample is determined to present
or absent by comparison to the internal negative controls for that sample. Counts corresponding
to “present” miRNAs are then normalized using a set of housekeeping genes, where the geometric
mean of housekeeping genes is calculated. The software then estimates the arithmetic mean of the
geometric means for all sample lanes. It derives the lane specific normalization factor by dividing the
arithmetic mean with geometric mean of each lane and multiples each count by this factor to give the
normalized value. These normalized counts are then compared between samples to get fold changes
between miRNAs expression. Relative fold change was calculated for each miRNA. This was achieved
by dividing the normalized count for a miRNA in the ALDEFLUOR positive sample by the count in
the ALDEFLUOR negative counterpart. Candidate miRNAs, which showed differential expression in
tumor ALDEFLUOR positive cells as compared to normal ALDEFLUOR positive cells, were selected
for further analysis. The heatmap in Figure 2 is representative of log2 fold changes of normalized
value of each miRNAs, centered and normalized to the mean of each lane. The miRNAs represented in
Figure 2 have a cut off p value significance of 0.1 or lower.
Prediction and analysis of gene targets for miRNAs. The predicted target transcripts of miRNAs
differentially expressed in CRC SCs were used to identify predicted target genes. Genome-wide
miRNA-mRNA target prediction was done using rna22 and TARGETSCAN by computationally
seeking “hits” on the 3’UTRs of all known transcripts as described [17].
Quantitative RT-PCR miRNA Assay. Quantitative RT-PCR was performed using a hydrolysis
probe(s)-type assay, RT-PCR kit, and miRNA-specific probes according to the manufacturer’s
instructions (Applied Biosystems, Foster City, CA & Life Technologies Inc., Carlsbad, CA) as follows.
Twenty nanograms of RNA were used in a final volume of 5 uL. Primer for the miRNA or U6 Control
(3 µL), dNTPs (0.15 µL), 10X PCR buffer (1.5 µL), RNAse Inhibitor (0.19 µL), RT enzyme (1.0 µL)
and water were added to make a final volume of 15 µl. The samples were mixed gently using a
sterile pipette and spun down briefly. The samples were placed in the thermocycler and cDNA was
synthesized using the following temperature conditions: 16 ◦ C for 30 min, 42 ◦ C for 30 min, 85 ◦ C
for 5 min and 4 ◦ C for 1 h. The cDNA (1.33 µL of RT product) was used to prepare the RT-PCR
reaction, which also contained 10ul of 2X PCR master mix (Applied Biosystems, no AmpErase UNG),
the primers provided in the kit and water to a final volume of 20 uL. The samples were prepared in
triplicates and added to the 96 well thermocycler plate (VWR Inc., Radnor, PA). The RT-PCR was run
using Applied Biosystems 7500 fast PCR machine for 95 ◦ C for 10 min followed by 40 cycles of 95 ◦ C for
15 s and 60 ◦ C for 1 min. The Ct value obtained was used to calculate the average Ct for each sample.
The fold change in expression of miRNA in treatment versus control samples was calculated using
the formula 2–(delta Ct (treatment) − delta Ct (control) . Four replicates were run per tumor/normal sample pair.
Any value greater than 2-fold change was regarded as significant. Statistical analysis was done by
Student’s T-test: Paired Two Sample for Means.
Transient Transfection. MicroRNA92a antimir and precursor siRNA molecules were purchased
from Ambion, Life Technologies. The amount of siRNA and transfection reagent (Lipofectamine 2000,
Invitrogen) was standardized for HT29 using a GFP coupled scrambled siRNA from DHARMACON
Inc., (Pittsburgh, PA). The cell lines were transfected in a 12 well or a 6 well plate and media was
changed 24 h post transfection. The increase or decrease of the miRNA levels was tested by the miRNA
RT-PCR Assay. The cells were analyzed 24–48 h post transfection.
Proliferation Assay. Cells were plated in triplicate per condition in 24-well plates and the initial
count was regarded as day 0. Seventy-two hours after treatment, cells were trypsinized, counted
and analyzed for viability by trypan blue dye exclusion using a Countess Cell counter (Invitrogen).
The enumerated cell numbers represented cell proliferation for day 3. Three independent sets of
experiment were carried out for each condition. Normalized fold change in cell count of HT29 cells
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with increased and decreased levels of miRNA92a was calculated by dividing the cell count of treatment
group as compared to control groups.
Luciferase Assay. Plasmids expressing luciferase and the 30 UTR of the predicted target gene, LRIG1,
was purchased from GeneCopoeia. Thirty-thousand HT29 cells were plated in a 96 well plate and
24 h later co-transfected with the luciferase vector and miRNA92a precursor and precursor control
molecules using Lipofectamine 2000. The media was changed 24 h post-transfection and the cells
were used for dual-color luciferase assay (Promega) and luminescence was recorded using the TECAN
plate reader.
Statistical Analysis. An Unpaired t-test was used to determine significance between the treatment
group and the appropriate controls. All the values obtained with a p-value less than 0.05 were
considered to be statistically significant and the corresponding miRNA a candidate for further
experimental validation.
5. Conclusions
Our goal was to determine if dysregulation of miRNAs is involved in the SC origin of CRC.
Accordingly, we used Nanostring-based miRNA expression profiling of ALDH-positive SC isolated
from normal colonic epithelium and CRC tissue. We found that miRNA92a is selectively expressed in
normal SCs and is aberrantly expressed in CRC SCs. Our further analysis revealed that miRNA92a
is a regulator of the LRIG1 stem cell gene. As discussed above, LRIG1 is a tumor suppressor gene,
which is involved in the inhibition of EGFR signaling. Indeed, LRIG1 was identified as a robust marker
for colonic SCs in humans as well as in mice [28,49]. Our findings indicate that increased levels of
miRNA92a diminish the tumor suppressive role of LRIG1 in the ALDEFLUOR-positive CSC population.
Taken together, our results suggest that miRNA92a is a critical contributor to the SC origin of CRC.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/8/2804/s1.
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ALDEFLUOR-positive tumor CSCs as compared to ALDEFLUOR-positive normal SCs.
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